[CFRX] ContraFect Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 77.83 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.25 Change: 0.1 (4.65%)
Ext. hours: Change: 0 (0%)

chart CFRX

Refresh chart

Strongest Trends Summary For CFRX

CFRX is in the long-term down -80% in 2 years and down -91% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding27.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV3.54 Price/Cash Per Share
Price/Free Cash Flow ROA-117.7% ROE-141.17% ROI
Current Ratio6.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.17
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit-4.49 M Operating Profit-4.7 M Total Assets25.31 M Total Current Assets23.15 M
Total Current Liabilities3.68 M Total Debt Total Liabilities4.21 M Total Revenue
Technical Data
High 52 week2.82 Low 52 week0.36 Last close0.49 Last change1.22%
RSI48.54 Average true range0.06 Beta0.54 Volume23.29 K
Simple moving average 20 days-5.58% Simple moving average 50 days0.82% Simple moving average 200 days-61.73%
Performance Data
Performance Week-4.69% Performance Month-16.97% Performance Quart11.34% Performance Half-76.56%
Performance Year-74.62% Performance Year-to-date-67.98% Volatility daily5.75% Volatility weekly12.86%
Volatility monthly26.36% Volatility yearly91.3% Relative Volume129.23% Average Volume1.13 M
New High New Low

News

2020-05-29 06:43:00 | CFRX: Four Abstracts Published in 30th ECCMID Abstract Book; Financing Overhang Removed as Pfizer Makes Second Investment…

2020-05-26 07:30:10 | ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

2020-05-22 07:10:20 | The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

2020-05-21 22:59:10 | ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

2020-05-21 16:09:38 | ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

2020-05-15 07:30:10 | ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-11 07:30:10 | ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

2020-04-21 07:00:10 | ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference

2020-03-30 05:00:10 | ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference

2020-03-23 06:15:00 | CFRX: Interim Futility Analysis for Phase 3 DISRUPT Trial Once 60% Enrolled…

2020-03-21 09:01:01 | We're Keeping An Eye On ContraFect's NASDAQ:CFRX Cash Burn Rate

2020-03-18 07:00:10 | ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

2020-03-04 07:00:10 | ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development

2020-02-24 07:00:10 | ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus MRSA Bacteremia, Including Right-Sided Endocarditis

2020-02-18 15:45:00 | CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…

2020-02-18 15:10:00 | CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…

2020-02-04 07:00:10 | ContraFect Announces One-for-Ten Reverse Stock Split

2020-02-03 07:00:10 | ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology

2020-01-27 07:00:10 | ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2020-01-22 07:00:10 | ContraFect to Present at 2020 ASM Biothreats

2020-01-21 05:00:00 | CFRX: Phase 3 DISRUPT Trial Underway…

2020-01-13 08:00:10 | ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

2020-01-10 07:00:10 | ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

2020-01-06 17:30:10 | ContraFect to Present at Biotech Showcase 2020

2020-01-04 07:30:00 | Pfizer Bought a Penny Biotech Stock Just Before It Doubled

2019-12-20 10:56:57 | Were Hedge Funds Right About Dumping ContraFect Corp CFRX?

2019-12-20 08:00:10 | ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

2019-12-18 07:00:10 | ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

2019-12-17 09:25:10 | ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

2019-12-16 07:30:10 | NexImmune Appoints Sol Barer as Chairman of the Board of Directors

2019-12-16 06:40:00 | CFRX: Financing Raises $12 Million, including $3 Million from Pfizer…

2019-12-10 08:46:39 | ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer

2019-12-10 07:56:02 | The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

2019-12-09 16:03:10 | ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

2019-11-29 09:00:10 | ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference

2019-11-18 08:05:00 | CFRX: Phase 3 Trial for Exebacase in MRSA Patients Underway Soon…

2019-11-12 07:00:00 | ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-05 07:00:00 | ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

2019-10-07 09:05:00 | CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19...

2019-10-03 07:34:18 | The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo

2019-10-02 07:00:00 | ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

2019-10-01 17:29:00 | ContraFect to Host Development Update Call and Webcast on October 2, 2019

2019-09-29 15:01:41 | The Week Ahead In Biotech Sept. 29-Oct. 5: Conference Presentations, IPOs Hit Top Gear

2019-09-26 07:00:00 | ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

2019-09-04 17:07:51 | ContraFect to Present at the 2019 Janney Healthcare Conference

2019-08-28 07:00:00 | ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

2019-08-16 10:45:00 | CFRX: Ready to Meet with the FDA Regarding Phase 3 Plan for Exebacase…

2019-08-09 07:00:00 | ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update

2019-07-01 09:13:00 | X-Biotix Therapeutics Joins Antimicrobials Working Group

2019-06-20 11:13:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019